A synthetic mammalian gene circuit reveals antituberculosis compounds

Synthetic biology provides insight into natural gene-network dynamics and enables assembly of engineered transcription circuitries for production of difficult-to-access therapeutic molecules. In Mycobacterium tuberculosis EthR binds to a specific operator (OethR) thereby repressing ethA and preventing EthA-catalyzed conversion of the prodrug ethionamide, which increases the resistance of the pathogen to this last-line-of-defense treatment. We have designed a synthetic mammalian gene circuit that senses the EthR–OethR interaction in human cells and produces a quantitative reporter gene expression readout. Challenging of the synthetic network with compounds of a rationally designed chemical library revealed 2-phenylethyl-butyrate as a nontoxic substance that abolished EthR's repressor function inside human cells, in mice, and within M. tuberculosis where it triggered derepression of ethA and increased the sensitivity of this pathogen to ethionamide. The discovery of antituberculosis compounds by using synthetic mammalian gene circuits may establish a new line of defense against multidrug-resistant M. tuberculosis.

[1]  James J. Collins,et al.  A Tunable Genetic Switch Based on RNAi and Repressor Proteins for Regulating Gene Expression in Mammalian Cells , 2007, Cell.

[2]  Martin Fussenegger,et al.  Synthetic ecosystems based on airborne inter- and intrakingdom communication , 2007, Proceedings of the National Academy of Sciences.

[3]  Martin Fussenegger,et al.  A synthetic time-delay circuit in mammalian cells and mice , 2007, Proceedings of the National Academy of Sciences.

[4]  James C. Sacchettini,et al.  Mechanism of thioamide drug action against tuberculosis and leprosy , 2007, The Journal of experimental medicine.

[5]  G. Besra,et al.  EthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets , 2007, Antimicrobial Agents and Chemotherapy.

[6]  M. Matsumoto,et al.  OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.

[7]  C. Locht,et al.  Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. , 2006, The Journal of antimicrobial chemotherapy.

[8]  Timothy S. Ham,et al.  Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.

[9]  Gürol M. Süel,et al.  An excitable gene regulatory circuit induces transient cellular differentiation , 2006, Nature.

[10]  Martin Fussenegger,et al.  Hysteresis in a synthetic mammalian gene network. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Fussenegger,et al.  Broad-spectrum protein biosensors for class-specific detection of antibiotics. , 2005, Biotechnology and bioengineering.

[12]  C. Locht,et al.  Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. , 2004, Molecular cell.

[13]  G. Besra,et al.  Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance. , 2004, Journal of molecular biology.

[14]  M. Fussenegger,et al.  An engineered epigenetic transgene switch in mammalian cells , 2004, Nature Biotechnology.

[15]  S. Ehlers,et al.  Lipoprotein processing is required for virulence of Mycobacterium tuberculosis † , 2004, Molecular microbiology.

[16]  Marc Aumercier,et al.  EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator , 2003, Molecular microbiology.

[17]  J. Keasling,et al.  Engineering a mevalonate pathway in Escherichia coli for production of terpenoids , 2003, Nature Biotechnology.

[18]  Jeff Hasty,et al.  Engineered gene circuits , 2002, Nature.

[19]  M. Fussenegger,et al.  Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. , 2002, Nucleic acids research.

[20]  M. Fussenegger,et al.  Macrolide-based transgene control in mammalian cells and mice , 2002, Nature Biotechnology.

[21]  R. Namdar,et al.  Population pharmacokinetics of ethionamide in patients with tuberculosis. , 2002, Tuberculosis.

[22]  Martin Fussenegger,et al.  SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus α-amylase , 2002 .

[23]  Christopher Dye,et al.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.

[24]  C. Locht,et al.  Activation of the pro-drug ethionamide is regulated in mycobacteria. , 2000, The Journal of biological chemistry.

[25]  L. Bekker,et al.  Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Kramer,et al.  Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis , 1999, Molecular microbiology.

[27]  D. Shiuan,et al.  Binding characteristics of Escherichia coli biotin repressor-operator complex. , 1991, Biochimica et biophysica acta.

[28]  M. Holdiness,et al.  Clinical Pharmacokinetics of the Antituberculosis Drugs , 1984, Clinical pharmacokinetics.

[29]  G. Hodges,et al.  Neurotoxicity of antibacterial agents , 1984, Annals of internal medicine.

[30]  W. Hillen,et al.  Binding of four repressors to double-stranded tet operator region stabilizes it against thermal denaturation , 1982, Nature.

[31]  K. Hollinrake.  Acute hepatic necrosis associated with ethionamide. , 1968, British journal of diseases of the chest.

[32]  J. Monod,et al.  Genetic regulatory mechanisms in the synthesis of proteins. , 1961, Journal of molecular biology.

[33]  Martin Fussenegger,et al.  SAMY, a novel mammalian reporter gene derived from Bacillus stearothermophilus alpha-amylase. , 2002, Gene.

[34]  H L Rieder,et al.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.